Sergio Rovner is an Endocrinology/Metabolic physician affiliated with University Medical Center of El Paso. OpenAlex indexes 14 publications with 2,420 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1516 Lomaland Dr.
El Paso, TX 79935
Telephone
915-593-2600Registry record last updated 2 May 2016.
Industry payments
59 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year202555 payments$30,575openpaymentsdata.cms.gov ↗
- Corcept TherapeuticsProgram year202546 payments$27,717openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202523 payments$15,769openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.1%GLP-1 receptor agonist16.9%Ozempic47%Mounjaro36%Trulicity13%Rybelsus5%Part D≥271 patientsInsulin Analog9.1%Lantus Solostar14%Tresiba Flextouch U-10014%Humalog Kwikpen U-10013%Toujeo Solostar12%Tresiba Flextouch U-20011%Insulin Lispro Kwikpen U-1009%Novolog Flexpen7%Toujeo Max Solostar5%Humalog Kwikpen U-2003%Humalog2%Insulin Lispro2%Levemir Flexpen2%Insulin Aspart Flexpen2%Basaglar Kwikpen U-1001%Soliqua 100-331%Fiasp1%Lantus1%Part D<11 patients+ 14 more classes in this area
Cardiovascular
28.4%Statin9.6%Atorvastatin Calcium56%Rosuvastatin Calcium34%Simvastatin8%Livalo1%Pravastatin Sodium1%Part D<11 patientsAngiotensin receptor blocker (ARB)3.6%Losartan Potassium53%Losartan-Hydrochlorothiazide13%Irbesartan12%Olmesartan Medoxomil11%Telmisartan5%Valsartan-Hydrochlorothiazide5%Olmesartan-Hydrochlorothiazide2%Part D<11 patients+ 15 more classes in this area
Hormonal (systemic)
16.1%l-Thyroxine13.5%Levothyroxine Sodium89%Synthroid11%Part D≥527 patientsl-Triiodothyronine1.1%Liothyronine Sodium100%Part D≥58 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”